Company intelligence / Profile preview
Lyra Therapeutics, Inc.
Watertown, Massachusetts, United Stateslyratherapeutics.com ↗
- Ownership
- Public · LYRA
- Employees
- ~30
- Development stage
- Phase 3
01
Overview
LYR-210 did not meet its primary endpoint in the ENLIGHTEN 1 Phase 3 trial as announced in May 2024. The company is awaiting results from the ENLIGHTEN 2 pivotal Phase 3 trial expected in Q2 2025. Post-hoc analyses in CRS patients with nasal polyps showed positive results in the ENLIGHTEN 1 Extension Study.
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Anti-inflammatory drug delivery systemsBioresorbable nasal implants
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
LianBio Inflammatory Limited
04
Financials
- Market cap
- $337.2K
- Total revenue
- $398K
- Enterprise value
- $14.7M
Beyond the preview
Go deeper on Lyra Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyra Therapeutics, Inc..